These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 24804271)

  • 1. Current vaccine trials in glioblastoma: a review.
    Xu LW; Chow KK; Lim M; Li G
    J Immunol Res; 2014; 2014():796856. PubMed ID: 24804271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial.
    Rapp M; Grauer OM; Kamp M; Sevens N; Zotz N; Sabel M; Sorg RV
    Trials; 2018 May; 19(1):293. PubMed ID: 29801515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma.
    Batich KA; Swartz AM; Sampson JH
    Expert Opin Biol Ther; 2015 Jan; 15(1):79-94. PubMed ID: 25327832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma.
    Phuphanich S; Wheeler CJ; Rudnick JD; Mazer M; Wang H; Nuño MA; Richardson JE; Fan X; Ji J; Chu RM; Bender JG; Hawkins ES; Patil CG; Black KL; Yu JS
    Cancer Immunol Immunother; 2013 Jan; 62(1):125-35. PubMed ID: 22847020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End.
    Datsi A; Sorg RV
    Front Immunol; 2021; 12():770390. PubMed ID: 34795675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of immunomodulation in human glioblastoma.
    Avril T; Vauleon E; Tanguy-Royer S; Mosser J; Quillien V
    Immunotherapy; 2011 Apr; 3(4 Suppl):42-4. PubMed ID: 21524170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular-based immunotherapies for patients with glioblastoma multiforme.
    Xu X; Stockhammer F; Schmitt M
    Clin Dev Immunol; 2012; 2012():764213. PubMed ID: 22474481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Personalized neoantigen vaccines: a glimmer of hope for glioblastoma.
    Londhe VY; Date V
    Expert Rev Vaccines; 2020 May; 19(5):407-417. PubMed ID: 32238056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Safety of available immunotherapy for the treatment of glioblastoma.
    Farber SH; Elsamadicy AA; Atik AF; Suryadevara CM; Chongsathidkiet P; Fecci PE; Sampson JH
    Expert Opin Drug Saf; 2017 Mar; 16(3):277-287. PubMed ID: 27989218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging immunotherapies for glioblastoma.
    Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
    Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report.
    Liau LM; Black KL; Martin NA; Sykes SN; Bronstein JM; Jouben-Steele L; Mischel PS; Belldegrun A; Cloughesy TF
    Neurosurg Focus; 2000 Dec; 9(6):e8. PubMed ID: 16817691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DCVax®-L--developed by Northwest Biotherapeutics.
    Polyzoidis S; Ashkan K
    Hum Vaccin Immunother; 2014; 10(11):3139-45. PubMed ID: 25483653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New perspectives in glioma immunotherapy.
    Daga A; Bottino C; Castriconi R; Gangemi R; Ferrini S
    Curr Pharm Des; 2011; 17(23):2439-67. PubMed ID: 21827420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Promising vaccines for treating glioblastoma.
    Swartz AM; Shen SH; Salgado MA; Congdon KL; Sanchez-Perez L
    Expert Opin Biol Ther; 2018 Nov; 18(11):1159-1170. PubMed ID: 30281978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma.
    Johanns TM; Garfinkle EAR; Miller KE; Livingstone AJ; Roberts KF; Rao Venkata LP; Dowling JL; Chicoine MR; Dacey RG; Zipfel GJ; Kim AH; Mardis ER; Dunn GP
    Clin Cancer Res; 2024 Jul; 30(13):2729-2742. PubMed ID: 38639919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma.
    Vik-Mo EO; Nyakas M; Mikkelsen BV; Moe MC; Due-Tønnesen P; Suso EM; Sæbøe-Larssen S; Sandberg C; Brinchmann JE; Helseth E; Rasmussen AM; Lote K; Aamdal S; Gaudernack G; Kvalheim G; Langmoen IA
    Cancer Immunol Immunother; 2013 Sep; 62(9):1499-509. PubMed ID: 23817721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens.
    Xu Q; Liu G; Yuan X; Xu M; Wang H; Ji J; Konda B; Black KL; Yu JS
    Stem Cells; 2009 Aug; 27(8):1734-40. PubMed ID: 19536809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma.
    Wen PY; Reardon DA; Armstrong TS; Phuphanich S; Aiken RD; Landolfi JC; Curry WT; Zhu JJ; Glantz M; Peereboom DM; Markert JM; LaRocca R; O'Rourke DM; Fink K; Kim L; Gruber M; Lesser GJ; Pan E; Kesari S; Muzikansky A; Pinilla C; Santos RG; Yu JS
    Clin Cancer Res; 2019 Oct; 25(19):5799-5807. PubMed ID: 31320597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccine-Based Immunotherapeutics for the Treatment of Glioblastoma: Advances, Challenges, and Future Perspectives.
    Cuoco JA; Benko MJ; Busch CM; Rogers CM; Prickett JT; Marvin EA
    World Neurosurg; 2018 Dec; 120():302-315. PubMed ID: 30196171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances and challenges: dendritic cell vaccination strategies for glioblastoma.
    Schaller TH; Sampson JH
    Expert Rev Vaccines; 2017 Jan; 16(1):27-36. PubMed ID: 27500911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.